Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CFO Sells $72,114.00 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 1,785 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.40, for a total value of $72,114.00. Following the sale, the chief financial officer now directly owns 106,169 shares in the company, valued at approximately $4,289,227.60. This trade represents a 1.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Ultragenyx Pharmaceutical Stock Up 0.2 %

Ultragenyx Pharmaceutical stock traded up $0.09 during trading hours on Friday, hitting $39.34. The stock had a trading volume of 401,537 shares, compared to its average volume of 780,638. Ultragenyx Pharmaceutical Inc. has a one year low of $36.87 and a one year high of $60.37. The stock has a market cap of $3.64 billion, a price-to-earnings ratio of -6.21 and a beta of 0.67. The business's 50 day simple moving average is $42.29 and its 200-day simple moving average is $48.13.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The company had revenue of $164.88 million for the quarter, compared to the consensus estimate of $163.23 million. Research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Remove Ads

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of hedge funds have recently made changes to their positions in the stock. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Ultragenyx Pharmaceutical during the fourth quarter worth about $5,505,000. Mackenzie Financial Corp grew its stake in Ultragenyx Pharmaceutical by 275.6% during the fourth quarter. Mackenzie Financial Corp now owns 16,115 shares of the biopharmaceutical company's stock worth $678,000 after purchasing an additional 11,825 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Ultragenyx Pharmaceutical during the fourth quarter worth approximately $82,000. Frazier Life Sciences Management L.P. grew its stake in Ultragenyx Pharmaceutical by 3.9% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 658,715 shares of the biopharmaceutical company's stock worth $27,712,000 after purchasing an additional 25,000 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Ultragenyx Pharmaceutical by 13.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,376 shares of the biopharmaceutical company's stock worth $8,514,000 after purchasing an additional 24,620 shares during the period. 97.67% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

RARE has been the topic of several analyst reports. Wells Fargo & Company increased their target price on Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a report on Friday, December 20th. JPMorgan Chase & Co. dropped their price objective on Ultragenyx Pharmaceutical from $105.00 to $102.00 and set an "overweight" rating for the company in a research report on Thursday, November 21st. Canaccord Genuity Group upped their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a research report on Tuesday, February 18th. HC Wainwright restated a "buy" rating and set a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Friday, February 14th. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, February 26th. One analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $93.50.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.